Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.381
-0.009 (-2.36%)
Jan 23, 2025, 12:29 PM EST - Market open
Relmada Therapeutics Employees
Relmada Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 6 or 42.86% compared to the previous year.
Employees
20
Change (1Y)
6
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$4,324,369
Market Cap
11.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RLMD News
- 6 weeks ago - Relmada discontinues late-stage trials for depression drug, explores sale - Reuters
- 6 weeks ago - Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 - GlobeNewsWire
- 7 weeks ago - Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why - Benzinga
- 7 weeks ago - Relmada's depression drug unlikely to meet main trial goal, analysis shows - Reuters
- 7 weeks ago - Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance - GlobeNewsWire
- 2 months ago - Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease - GlobeNewsWire
- 2 months ago - Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript - Seeking Alpha